CurrentCignaPolicy IP0132

Desmopressin acetate (Noctiva) — Coverage Criteria for Nocturia due to Nocturnal Polyuria

Defines medical necessity, authorization, and reauthorization criteria for coverage of Noctiva (desmopressin nasal spray) in adults with nocturia due to nocturnal polyuria for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyDesmopressin acetate (Noctiva) — Coverage Criteria for Nocturia due to Nocturnal Polyuria

Policy CodePolicy IP0132

Change TypeNo material changes

Effective DateMar 15, 2025

Next Review DateN/A

Key ActionObtain prior authorization and document age, 24-hour urine confirming nocturnal polyuria, frequency of nocturnal voids (≥2/night), baseline serum sodium, prior conservative measures, and contraindication checklist.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥50Minimum age

12 moAuth duration

≥2/nightSymptom frequency

135–145Serum sodium

≥50eGFR threshold

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Noctiva (desmopressin nasal spray)

Initial Therapy Criteria

Covered when ALL of the following are met:

Initial coverage criteria: Member meets ALL criteria A–G

A: Age: Age 50 years or older>=50 years

chunk 4

B: Diagnosis confirmation: Documented diagnosis of nocturnal polyuria confirmed by 24-hour urine collection before treatment initiation and meets the age-specific nocturnal urine volume thresholdsee thresholds

chunks 4,5

C: Symptom frequency: Awakens at least 2 times per night to void prior to therapy>=2/night

chunk 5

D: Baseline labs: Serum sodium concentrations within the normal range (135 to 145 mmol/L) prior to therapy135-145 mmol/L

chunk 5

E: Contraindications absent: Prescriber has verified absence of contraindicated conditions: current loop diuretic use, current systemic or inhaled glucocorticoids, renal impairment with eGFR < 50 mL/min/1.73 m2, NYHA class II–IV congestive heart failure, polydipsia, or known/suspected SIADH

chunk 5

F: Prior conservative measures: Tried non-pharmacologic techniques or lifestyle interventions (e.g., nighttime fluid restriction, avoidance of caffeine/alcohol, earlier timing of medications, leg elevation, compression stockings) prior to desmopressin

chunk 5

G: Prescriber specialty: Medication prescribed by or in consultation with a urologist, geriatrician, or endocrinologist

chunk 5

Reauthorization / Continuation Therapy

Covered when ALL of the following are met:

Reauthorization criteria: All initial medical necessity criteria remain met AND there is documentation of beneficial response to therapy

chunk 6

Not Medically Necessary / Exclusions

Excluded uses: Any other use is considered experimental, investigational, or unproven, including primary nocturnal enuresis; Noctiva is contraindicated for primary nocturnal enuresis due to hyponatremia risk observed with pediatric intranasal desmopressin formulations

chunk 8

Any use of Noctiva (desmopressin nasal spray) for indications not listed as covered in this policy is considered experimental, investigational, or unproven. This includes use for primary nocturnal enuresis, which is specifically contraindicated due to reported hyponatremia-related seizures in pediatric patients treated with other intranasal desmopressin formulations. Providers should not request authorization for off‑label or non‑listed indications under this policy.

Use of Noctiva for primary nocturnal enuresis (pediatric enuresis) is contraindicated and considered not medically necessary under this policy. Reports of hyponatremia-related seizures in pediatric patients treated with other intranasal desmopressin formulations and the absence of pediatric trials for Noctiva support this exclusion.

Clinical and Laboratory Thresholds

inv-06: Nocturnal urine volume thresholds by age group

Age <65 thresholdNocturnal urine volume >20% of 24‑hour urine volume

Age ≥65 thresholdNocturnal urine volume >33% of 24‑hour urine volume

Confirmation methodConfirmed by 24‑hour urine collection prior to treatment initiation

inv-07: Serum sodium — required baseline range

Required baseline rangeSerum sodium 135 to 145 mmol/L

Monitoring recommendationCheck serum sodium prior to initiating or resuming therapy and throughout treatment

Contraindication noteUse is contraindicated in patients with hyponatremia or a history of hyponatremia

inv-08: Estimated glomerular filtration rate (eGFR) threshold

Minimum eGFR for useeGFR must be ≥ 50 mL/min/1.73 m2

ContraindicationDo not use in patients with renal impairment with eGFR < 50 mL/min/1.73 m2

Related safety guidanceAvoid use during illnesses that may cause fluid or electrolyte imbalance

Provider Requirements and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization required for initial therapy. Initial approval duration up to 12 months when all medical necessity criteria are met.

Initial approval duration: up to 12 months
Reauthorization: up to 12 months

Documentation Required

Documentation Requirements

Documentation must include patient age and objective confirmation of nocturnal polyuria with a 24‑hour urine collection, plus baseline frequency of nocturnal voids (≥2/night) and baseline serum sodium and renal function labs.

Document age (must be ≥ 50 years for initiation per criteria)
24‑hour urine collection demonstrating nocturnal polyuria (nocturnal urine volume >20% of 24‑hr total if <65 y; >33% if ≥65 y)
Baseline frequency of nocturnal voids (≥2/night)
Baseline serum sodium and eGFR values

Note

Trial of Non‑pharmacologic Interventions Required

Policy requires that non‑pharmacologic interventions be tried and documented prior to initiating therapy.

Examples: nighttime fluid restriction (limit caffeine/alcohol), timing of diuretics/other meds earlier in day, leg elevation, compression stockings, emptying bladder before bed, weight/edema management

Denial Risk

Contraindications / Denial Risks

Use is contraindicated and will be denied for patients with conditions that increase risk of hyponatremia or adverse events.

Hyponatremia or history of hyponatremia (serum sodium <135 mmol/L) — contraindicated
Renal impairment with eGFR <50 mL/min/1.73 m2 — contraindicated
NYHA class II–IV congestive heart failure — contraindicated; use caution in NYHA class I
Polydipsia or known/suspected SIADH — contraindicated
Concurrent use of loop diuretics or systemic/inhaled glucocorticoids — not recommended
Concurrent illness that may cause fluid/electrolyte imbalance (e.g., gastroenteritis) — avoid

OpenPayer

Desmopressin acetate (Noctiva) — Coverage Criteria for Nocturia due to Nocturnal Polyuria

Coverage Criteria for Noctiva (desmopressin nasal spray)

Clinical and Laboratory Thresholds

Provider Requirements and Prior Authorization

Definitions and Diagnostic Criteria

Background